Skip to main content
OpenTrials
Completed

NCT Number: NCT03228992

Ibuprofen Versus Placebo For Muscle Soreness

The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Jean Brown Research

Salt Lake City, Utah, 84124, United States

About this study

This is a double-blind, randomized, placebo controlled, parallel group, pilot safety and efficacy study. Healthy male or female subjects who have a history of occasional muscle soreness and are not currently exercising will be asked to volunteer for the study. All subjects will complete an informed consent process prior to study procedures.

The study duration is anticipated to be approximately 4 months. Each subject may be in the study for up to 45 days including screening, run-in, inpatient and outpatient dosing and assessments, follow-up visit and follow-up telephone contact.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Subjects must meet the following criteria to be included in the study:

  • Male or female subjects aged 18-55 years;
  • In good general health;
  • Non-pregnant, non-lactating female subjects must be:
  • physically incapable of childbearing potential (postmenopausal for more than 1 year or surgically sterile) or
  • practicing an acceptable method of contraception (hormonal, barrier with spermicide, intrauterine device, vasectomized or same sex partner, or abstinence). Subjects using hormonal birth control must have been on a stable dose of treatment for at least 30 days and received at least 1 cycle of treatment prior to randomization.
  • History of experiencing muscle pain/soreness after moderately strenuous exercise;

Subjects are excluded from the study if any of the following criteria apply:

  • Currently participating in an exercise regimen.
  • Have an allergy or intolerance to any NSAID, aspirin, acetaminophen or lactose;
  • History of rhabdomyolysis;
  • Have participated in an investigational study within the past 30 days of screening;
  • Are an employee or relative of an employee of the study site (directly involved with the study).

Treatment and study plan

Ibuprofen 400 mg

Drug

Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.

Placebo

Other

Subjects will receive 4 doses of placebo over a 24 hour period.

Primary outcomes

  1. Model Sensitivity

    Time frame: 24 hours

    Assess whether ibuprofen provides more relief than placebo in the DOMS model.

Sponsors and collaborators

Lead sponsor

Jean Brown Research

Other

Registry information

Official study title

A DOUBLE-BLIND, REPEAT-DOSE, PARALLEL GROUP, PILOT STUDY COMPARING THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED IBUPROFEN AND PLACEBO IN DELAYED ONSET MUSCLE SORENESS

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jul 25, 2017
Registry last updated
Aug 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.